MONOPAR THERAPEUTICS INC
MNPRNASDAQTrading Snapshot
- Day Range
- $79.57 – $80.81
- 52-Week Range
- $50.07 – $124.82
- Volume
- $2.11B
- Avg Volume
- $2.23B
- Shares Outstanding
- 6.7M
- Next Earnings
- Nov 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $64M
- Last Q Revenue
- $18M
- P/E Ratio
- -35.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.09
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −41.7%
Why Investors Own MNPR
- ✓High-growth profile — revenue up +59.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MONOPAR THERAPEUTICS INC
MNPR
StockOtter · stockotter.spaceAbout MONOPAR THERAPEUTICS INC
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast
Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength
Monopar Appoints Jeffrey D. Kent, M.D.
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for ALXN1840 in the coming mon
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahe
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet